One of the leading companies racing to develop psychedelics as legal medicines was granted a patent last week for a formulation of psilocybin the hallucinogenic compound found in magic mushrooms a decision that highlights the increasingly intense battle around intellectual property for potential medicines in this rapidly growing sector.
This is Compass Pathways fourth U.S. patent, but its first for a form of psilocybin the company isnt using in its clinical trials on treatment-resistant depression. The patent works to expand their intellectual property kingdom, said Mason Marks, senior fellow and project lead on the Project on Psychedelics Law and Regulation at Harvard Law School: Like a landlord would want to expand and buy more properties, theyre trying to lock up as much IP as they can to solidify their position in the market.
The patent, which covers a form of synthetic psilocybin known as Form A hydrate and methods of producing it, is useful to Compass as a way to restrict competitors who may be working with a different form of psilocybin. If another company creates psilocybin using that particular structure, then Compass will now have grounds to block them.
advertisement
I have no doubts the reasons behind this are to protect a competitive position around psilocybin, said Graham Pechenik, patent attorney and founder of Calyx Law. The latest patent decision is likely to be challenged by those who believe that Form A hydrate is not new, and so cannot be patented.
Compass defended its decision to seek a patent for its formulation. As always were expecting challenges, said Compasss co-founder and president Lars Christian Wilde. We believe what weve found is novel and inventive. Were confident in our IP strategy.
advertisement
Research and investment in psychedelics has accelerated in recent years. The U.S. Food and Drug Administration has granted breakthrough therapy designation to psilocybin and MDMA (also known as molly or ecstasy), for treatment of depression and PTSD, respectively, a sign that the agency is open to approval if the drugs are shown to be effective and safe in trials. The potential market is huge and extremely lucrative, predicted to be valued at $7 billion by 2027, according to an analysis from Data Bridge Market Research.
Psychedelic drugs, though, both exist in nature and have been studied for decades MDMA was first synthesized in 1912 and psilocybin in 1958. This makes it challenging for pharmaceutical companies to follow traditional approaches of patenting newly discovered drugs to protect their investments and fend off competitors. Instead, companies are creating more niche patents, such as Compasss IP on various forms of psilocybin: They need to figure out how to protect this naturally occurring substance, said Citi analyst Neena Bitritto-Garg. (Citigroup has received compensation from atai life sciences, which owns more than 20% of Compass, for investment banking and other services.)
There is also considerable debate and competition within the industry about whether and how these drugs should be patented. Compass is due to publish results from a Phase 2b trial with 233 patients for psilocybin therapy for treatment-resistant depression before the end of this year. Meanwhile, the non-profit Usona Institute, which is anti-patent, is running a Phase 2b psilocybin trial for people with major depressive disorder.
Carey Turnbull, a philanthropist who is a board member of several psychedelic non-profits including Usona Institute, created another non-profit, Freedom to Operate, to fight patents that infringe on existing knowledge. He believes Compasss latest patent should not stand.
From FTOs ongoing research, we understand that it is nearly impossible to crystallize psilocybin and not obtain this hydrate, Turnbull wrote to STAT. There are several examples of it in the prior art. He declined to give details of the existing examples while still putting together a report.
Usona itself is not worried about psilocybin patents affecting its work, said president Bill Linton: The non-profit is using a version of the drug that has been in the public domain since 1958.
Psychedelic patents are currently so turbulent, with waves of applications and challenges, in part because many patent examiners are unfamiliar with the space and the existing research, said Marks. The Usona Institute is currently building out a library of existing research, Porta Sophia Psychedelic Prior Art Library, to help prevent patents being awarded on pre-existing knowledge. Psilocybin was first synthesized in the 1950s and, given the large numbers of laboratories, Marks said hes doubtful there are truly novel formulations left to be patented.
Even among psychedelic patents that meet the technical definition of novelty, the rush to protect formulations simply to block competition, rather than patenting an innovation thats useful to patients, is contrary to the spirit of IP law, said Marks. U.S. patent law technically requires utility, but this is rarely applied in practice: Effectively it doesnt exist. Other countries, such as India, are far more strict about creating patents that are useful for patients, making IP grabs more difficult, as Marks outlines in a forthcoming Harvard Law Review Forum on psychedelic patents.
It could be a patent on something thats useless, said Marks on the Compasss latest patent. I would not make any assumption that it makes any real benefit.
Different formulations of psilocybin could have varying levels of effectiveness, and Wilde of Compass said the company is exploring whether the latest form could be particularly beneficial under certain conditions.
In his view, all patents are beneficial. IP allows companies to protect innovation, and therefore finance research and bring drugs to patients, he said: Any patent therefore is in the interest of patients and more broadly in the interest of the field.
Those pushing back argue that a small number of companies owning the rights to these drugs will make any treatments that are approved more expensive. If the FDA approves psilocybin following Compass Pathways research, for example, only the patented synthetic version of the drug would be legal medicine, rather than the naturally occurring substance. It will affect the barriers to entry for scientific research and the cost to accessing these therapies, said Marks.
For investors, the crucial question is whether patents are approved and withstand challenges. Ethical questions are less of a concern, said Citis Bitritto-Gard: Investors are profit-seeking.
So as psilocybin slowly edges toward approval as a medicine, fights over every line of intellectual property are likely to grow fiercer. The eventual patent decisions will determine who controls the supply of psilocybin, and who profits off this hallucinogenic drug.
Correction: An earlier version of this story misstated the date when psilocybin was first synthesized.
View post:
Psilocybin patent highlights the swirling battle over psychedelics IP - STAT - STAT
- 8 Mystical Herbs and Legal Psychedelics For Lucid Dreaming - December 8th, 2016 [December 8th, 2016]
- Psychedelics: LSD, Mushrooms, Salvia | Facts | Drug Policy ... - December 10th, 2016 [December 10th, 2016]
- FS Book Company - Marijuana Books - December 12th, 2016 [December 12th, 2016]
- Psychedelic - PsychonautWiki - December 27th, 2016 [December 27th, 2016]
- From Alzheimer's To Psychedelics, 2016 Was A Good Year For ... - January 3rd, 2017 [January 3rd, 2017]
- LSD - Psychedelic Effects - The Good Drugs Guide - January 5th, 2017 [January 5th, 2017]
- THC - Psychedelics - January 29th, 2017 [January 29th, 2017]
- Psychedelics | Pharmacological Reviews - January 30th, 2017 [January 30th, 2017]
- Dorian Yates reveals all on steroids, body dysmorphia, psychedelics, cannabis and yoga - Express.co.uk - February 7th, 2017 [February 7th, 2017]
- Psychedelic drug therapy including magic mushrooms, LSD and ... - CBS News - February 7th, 2017 [February 7th, 2017]
- Psychedelics Being Tested For Use In Treating Various Conditions - CBS Local - February 8th, 2017 [February 8th, 2017]
- The psychedelic renaissance - Boulder Weekly - February 9th, 2017 [February 9th, 2017]
- Buy psychedelics online : Chinglabs.com - February 12th, 2017 [February 12th, 2017]
- Psychedelic drugs like magic mushrooms and LSD have key ... - Yahoo Finance - February 13th, 2017 [February 13th, 2017]
- Psychedelics a Viable Therapeutic Option for Depression - Psychiatry Advisor - February 14th, 2017 [February 14th, 2017]
- Is Silicon Valley Onto Something With Its LSD Microdosing? - Newsweek - February 15th, 2017 [February 15th, 2017]
- News Releases - Noozhawk - February 16th, 2017 [February 16th, 2017]
- A Revolution in the Science of Psychedelics is Happening in Boulder - 303 Magazine - February 16th, 2017 [February 16th, 2017]
- When Reality Is More Intense Than Psychedelics: Strand Of Oaks ... - NPR - February 17th, 2017 [February 17th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - AlterNet - February 22nd, 2017 [February 22nd, 2017]
- Psychedelics May Help Reduce Opioid Addiction, According To ... - Huffington Post - February 23rd, 2017 [February 23rd, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - eNews Park Forest - February 24th, 2017 [February 24th, 2017]
- Psychedelics Could Play A Role In Tackling The Opioid Epidemic - Huffington Post - February 24th, 2017 [February 24th, 2017]
- Meet The People's Champion of Psychedelic Drugs - Narratively - February 27th, 2017 [February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way ... - Yahoo Finance - February 27th, 2017 [February 27th, 2017]
- First U. student group on studying psychedelics holds open house - The Daily Princetonian - February 27th, 2017 [February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way people see the world - Businessinsider India - February 28th, 2017 [February 28th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New ... - February 28th, 2017 [February 28th, 2017]
- WATCH: A Public Policy Expert Explains How to Safely Deregulate LSD and Other Psychedelics - AlterNet - March 7th, 2017 [March 7th, 2017]
- Quotes About Psychedelics (48 quotes) - March 7th, 2017 [March 7th, 2017]
- Inside the Psychedelic Underground - RollingStone.com - March 9th, 2017 [March 9th, 2017]
- What Psychedelics Really Do to Your Brain - Rolling Stone - RollingStone.com - March 10th, 2017 [March 10th, 2017]
- Hallucinogens Help, According to a Mom's Memoir and Son's Documentary - Bedford + Bowery - April 8th, 2017 [April 8th, 2017]
- Meditation and the psychedelic drug ayahuasca seem to change the brain in surprisingly similar ways - Businessinsider India - April 8th, 2017 [April 8th, 2017]
- Tripping out: the highs and lows of psychedelic therapy - Marie Claire UK - April 8th, 2017 [April 8th, 2017]
- Stop Policing Psychedelic Science - Motherboard - June 6th, 2017 [June 6th, 2017]
- America's Trippiest Chemist: Making Psychedelics 'Was Fun' - Motherboard - June 6th, 2017 [June 6th, 2017]
- The Three Types of Hallucinogens: Psychedelics ... - June 7th, 2017 [June 7th, 2017]
- Cary Grant was one of the first to benefit from LSD therapy - Quartz - June 11th, 2017 [June 11th, 2017]
- What it's like to take psychedelics in small doses at breakfast - New Scientist - June 14th, 2017 [June 14th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - Religion News Service - June 14th, 2017 [June 14th, 2017]
- Q&A With Psychedelic Stand-Up and LaughFest Headliner Shane Mauss - Flagpole Magazine - June 20th, 2017 [June 20th, 2017]
- Q&A: LaughFest comedian talks science and psychedelics - Red and Black - June 20th, 2017 [June 20th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Daily Tribune - June 21st, 2017 [June 21st, 2017]
- Shane Mauss brings Good Trip Comedy Tour to town - Chattanooga Times Free Press - June 22nd, 2017 [June 22nd, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Oakland Press - June 22nd, 2017 [June 22nd, 2017]
- Director Ana Lily Amirpour on Cannibalism, Psychedelics, and 'Horrifying' Racism Allegations - Jezebel - June 23rd, 2017 [June 23rd, 2017]
- Majority of Americans ready to embrace psychedelic therapy - YouGov US - June 24th, 2017 [June 24th, 2017]
- The Refugee Funding America's Psychedelic Renaissance - VICE - June 24th, 2017 [June 24th, 2017]
- Open Your Mind This Weekend at Europe's Largest Psychedelic Conference - VolteFace Magazine (blog) - June 27th, 2017 [June 27th, 2017]
- Psychedelics and Virtual Reality Make a Trendy but Illegal Therapy - Inverse - June 27th, 2017 [June 27th, 2017]
- The war on drugs is back. Will psychedelic drug research survive? - The Verge - June 29th, 2017 [June 29th, 2017]
- Tune in, Turn on, Stay in School - Study Breaks - July 2nd, 2017 [July 2nd, 2017]
- Cannabist Show: He's psychedelic comedian Shane Mauss - The Cannabist - July 2nd, 2017 [July 2nd, 2017]
- The brain on DMT: mapping the psychedelic drug's effects - Wired.co.uk - July 3rd, 2017 [July 3rd, 2017]
- Psychedelics Could Help Asia's Mental Health Care, But Stigma Remains Roadblock - TheFix.com - July 3rd, 2017 [July 3rd, 2017]
- Is LSD the new coffee? - FactorDaily - July 4th, 2017 [July 4th, 2017]
- My grandfather was a death row doctor. He tested psychedelic drugs on Texas inmates. - Texas Tribune - July 5th, 2017 [July 5th, 2017]
- About Us | Trusted News Source for Psychedelic Research ... - July 6th, 2017 [July 6th, 2017]
- Do Psychedelic Drugs Cause the 'Prophetic Effect'? - Breaking Israel News - July 11th, 2017 [July 11th, 2017]
- Are psychedelics the new medical marijuana? - WTSP 10 News - July 14th, 2017 [July 14th, 2017]
- Psychiatrists Say Cannabis Medicine Has Psychedelic Properties - The Marijuana Times - July 15th, 2017 [July 15th, 2017]
- Can Psychedelics Be Therapy? Allow Research to Find Out - New York Times - July 17th, 2017 [July 17th, 2017]
- Countdown To (Legalized) Ecstasy! Rick Doblin, MAPS, & the Psychedelic Renaissance [Podcast] - Reason (blog) - July 20th, 2017 [July 20th, 2017]
- Should We Reclassify Marijuana as a Hallucinogen? - Big Think - July 20th, 2017 [July 20th, 2017]
- Do You Take Drugs at Festivals? This Initiative is Working on Keeping You Safe - PoliticalCritique.org - July 20th, 2017 [July 20th, 2017]
- Psychedelic drugs could tackle depression in a way that antidepressants can't - INSIDER - July 22nd, 2017 [July 22nd, 2017]
- Psychedelic Shine takes a trip to the skies in Boulder - Boulder Daily Camera - July 22nd, 2017 [July 22nd, 2017]
- Reasons to Consider Trying Psychedelics - FoxWeekly - July 27th, 2017 [July 27th, 2017]
- Psychedelics and Normality - HuffPost - July 27th, 2017 [July 27th, 2017]
- New book about psychedelics and weird human experiences - Boing Boing - July 27th, 2017 [July 27th, 2017]
- Scientists Want You to Give Them Money to Study ... - July 29th, 2017 [July 29th, 2017]
- What Has Awe Done for Me Lately? - HuffPost - August 1st, 2017 [August 1st, 2017]
- For children, it's beyond psychedelics - The Hans India - The Hans India - August 1st, 2017 [August 1st, 2017]
- Expanding consciousness - 48 Hills - August 2nd, 2017 [August 2nd, 2017]
- THE FUTURE OF PSYCHEDELICS: Are LSD and Mushrooms The New Prozac? - Dope Magazine - August 5th, 2017 [August 5th, 2017]
- Psychedelic drugs saved my life. So why aren't they prescribed? - Wired.co.uk - August 9th, 2017 [August 9th, 2017]
- LSD as therapy: How scientists are reclaiming psychedelics ... - August 9th, 2017 [August 9th, 2017]
- The foundation of Western philosophy is probably rooted in psychedelics - Quartz - August 12th, 2017 [August 12th, 2017]
- Crazy Enough to be Correct - HuffPost - August 15th, 2017 [August 15th, 2017]